Copyright
©The Author(s) 2019.
World J Clin Oncol. Mar 24, 2019; 10(3): 136-148
Published online Mar 24, 2019. doi: 10.5306/wjco.v10.i3.136
Published online Mar 24, 2019. doi: 10.5306/wjco.v10.i3.136
Table 4 Table of chi-square test of association between fibroblast growth factor receptor 4 genotypes (Gly/Gly and Gly/Arg or Arg/Arg), Lymph nodes, tumor stage, and recurrence status
| Fibroblast growth factor receptor 4 genotype | |||||
| Gly388 | Arg388 | n | P-value | ||
| Positive lymph nodes | N0, N1 and N2 | 644 | 295 | 939 | 0.010 |
| N3 | 75 | 17 | 92 | ||
| Tumor stage | T1 and T2 | 491 | 86 | 577 | 0.0001 |
| T3 and T4 | 228 | 226 | 454 | ||
| Recurrence status | 0 | 574 | 208 | 782 | 0.0001 |
| 1 | 145 | 104 | 249 | ||
- Citation: Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148
- URL: https://www.wjgnet.com/2218-4333/full/v10/i3/136.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i3.136